See more : Edgewater Wireless Systems Inc. (YFI.V) Income Statement Analysis – Financial Results
Complete financial analysis of BioHarvest Sciences Inc. (CNVCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioHarvest Sciences Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- MDxHealth SA (MXDHF) Income Statement Analysis – Financial Results
- Geotech Holdings Ltd. (1707.HK) Income Statement Analysis – Financial Results
- UOB-Kay Hian Holdings Limited (U10.SI) Income Statement Analysis – Financial Results
- Hokuriku Electric Power Company (9505.T) Income Statement Analysis – Financial Results
- Westcore Energy Ltd. (WRRNF) Income Statement Analysis – Financial Results
BioHarvest Sciences Inc. (CNVCF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.bioharvest.com
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc., together with its subsidiaries, offers nutraceutical super fruits and cannabis verticals in Israel and internationally. Its plant cell growth technology produces the active secondary metabolites without the need to grow the plant itself. The company designs, develops, manufactures, and markets Vinia, a red grape powder nutraceutical product; and medical cannabis. BioHarvest Sciences Inc. is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.67M | 5.50M | 2.10M | 396.00K | 218.00K | 449.00K | 325.00K | 40.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 7.04M | 4.28M | 1.43M | 258.00K | 189.00K | 463.00K | 493.00K | 240.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.63M | 1.22M | 670.00K | 138.00K | 29.00K | -14.00K | -168.00K | -200.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 44.45% | 22.17% | 31.87% | 34.85% | 13.30% | -3.12% | -51.69% | -500.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.37M | 2.31M | 4.13M | 1.26M | 1.35M | 553.00K | 429.00K | 388.00K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.68M | 5.05M | 1.80M | 4.57M | 848.00K | 778.00K | 160.55K | 89.51K | 118.52K | 189.50K | 60.75K |
| Selling & Marketing | 6.40M | 4.30M | 2.96M | 467.00K | 145.00K | 484.00K | 422.00K | 3.28K | 8.41K | 9.31K | 9.51K |
| SG&A | 12.07M | 9.35M | 4.76M | 5.04M | 993.00K | 1.46M | 160.55K | 92.78K | 126.94K | 198.81K | 70.25K |
| Other Expenses | 156.00K | 171.00K | 273.00K | 0.00 | 0.00 | 0.00 | 249.91 | 483.67 | 525.74 | 273.62 | 0.00 |
| Operating Expenses | 15.60M | 11.83M | 9.16M | 6.30M | 2.34M | 5.47M | 160.80K | 93.27K | 127.46K | 199.08K | 70.25K |
| Cost & Expenses | 22.64M | 16.11M | 10.59M | 6.56M | 2.53M | 5.93M | 160.80K | 93.27K | 127.46K | 199.08K | 70.25K |
| Interest Income | 0.00 | 0.00 | 0.00 | 193.00K | 758.00K | 1.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 936.00K | 508.00K | 805.00K | 611.00K | 3.76M | 0.00 | 3.95K | 6.54K | 2.15K | 1.93K | 406.17 |
| Depreciation & Amortization | 840.00K | 712.00K | 389.00K | 288.00K | 324.00K | 70.00K | 84.00K | 102.00K | 525.74 | 273.62 | 0.00 |
| EBITDA | -9.76M | -9.99M | -8.63M | -5.77M | -1.98M | -1.95M | -1.65M | -2.08M | -126.94K | -198.81K | -70.25K |
| EBITDA Ratio | -77.04% | -181.63% | -387.68% | -1,435.61% | -563.30% | -435.19% | -49.12% | -231.96% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.97M | -10.61M | -8.49M | -6.17M | -2.31M | -2.02M | -159.88K | -93.27K | -127.46K | -199.08K | -70.25K |
| Operating Income Ratio | -78.65% | -193.02% | -403.95% | -1,557.07% | -1,059.63% | -450.78% | -49.19% | -233.17% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.60M | -624.00K | -1.34M | -418.00K | -3.00M | -2.66M | -108.00K | 2.09M | -2.15K | -1.93K | -406.17 |
| Income Before Tax | -12.56M | -11.24M | -9.83M | -6.58M | -5.31M | -7.47M | -163.83K | -99.80K | -129.61K | -201.01K | -70.66K |
| Income Before Tax Ratio | -99.15% | -204.37% | -467.51% | -1,662.63% | -2,435.78% | -1,664.14% | -50.41% | -249.51% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -861.00K | 805.00K | 611.00K | 3.76M | -799.00K | 3.95K | 6.54K | 2.15K | 1.93K | 0.00 |
| Net Income | -12.56M | -11.24M | -9.83M | -6.58M | -5.31M | -6.67M | -1.85M | -3.50M | -131.76K | -201.01K | -70.66K |
| Net Income Ratio | -99.15% | -204.37% | -467.51% | -1,662.63% | -2,435.78% | -1,486.19% | -568.00% | -8,747.50% | 0.00% | 0.00% | 0.00% |
| EPS | -0.93 | -0.86 | -0.79 | -0.68 | -1.80 | -16.80 | 0.00 | 0.00 | -0.01 | -0.02 | -0.04 |
| EPS Diluted | -0.93 | -0.86 | -0.79 | -0.68 | -1.80 | -16.80 | 0.00 | 0.00 | -0.01 | -0.02 | -0.04 |
| Weighted Avg Shares Out | 13.53M | 13.05M | 12.45M | 9.71M | 2.95M | 397.20K | 0.00 | 0.00 | 13.76M | 12.16M | 2.00M |
| Weighted Avg Shares Out (Dil) | 13.53M | 13.05M | 12.45M | 9.71M | 2.95M | 397.20K | 0.00 | 0.00 | 13.76M | 12.16M | 2.00M |
BioHarvest Sciences launches first major US marketing campaign for VINIA
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) has announced the first multimedia campaign for its flagship VINIA wellness supplement in the United States. The company said it is scaling up its US marketing in line with a 2022 growth plan that aims...
BioHarvest Sciences wins its largest ever VINIA purchase order from Batory Foods
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) said Batory Foods has placed a purchase order for 1,000 kg of its flagship VINIA wellness supplement to be delivered by the end of December this year. Batory Foods is one of the top three companies in...
BioHarvest Sciences reports strong 2Q sales of VINIA wellness product as production scales up at new Israel facility
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) announced record sales of its flagship VINIA wellness supplement in the second quarter of 2022, with US$947,000 in revenue. The company said that sales of VINIA, a clinically proven blood flow superfood, increased by 99%...
BioHarvest Sciences appoints experienced investment banking executive Gavriel Lambert to board of advisors
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) said it has appointed experienced investment banking executive Gavriel Lambert to its board of advisors with immediate effect. Lambert, who has held positions at Barclays, Solomon Smith Barney, JP Morgan and UBS Securities, has 27...
BioHarvest Sciences hires Dr Brian Cornblatt as its chief medical officer
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) said it has hired Dr Brian S. Cornblatt as its chief medical officer, marking a “significant milestone” in its plan to develop next generation therapeutic solutions, including botanical drugs.
BioHarvest Sciences reveals unique composition profile of cannabis products suitable for medical and food and beverage applications
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) has unveiled the composition profile of its full-spectrum cannabis produced from large-scale industrial bioreactors based on its proprietary Bio-Plant CELLicitation platform. BioHarvest told investors testing has demonstrated that the composition profile includes the cannabis compounds THC, CBD, CBG,...
BioHarvest Sciences to raise up to US$5M in convertible notes to finance growth plans
BioHarvest Sciences Inc has revealed plans to raise up to US$5 million via convertible notes, which it says will finance the growth plans for its polyphenols/antioxidants and cannabis business lines. "Our unprecedented achievements to date in the development and commercialization...
BioHarvest Sciences reports 1Q sales of flagship nutraceutical VINIA product increased by triple digits year-on-year
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) announced that sales of its flagship nutraceutical VINIA product increased by triple digits year-on-year in the first quarter of 2022. VINIA sales reached US$787,000, representing a jump of 112% versus the year-ago quarter, according to...
BioHarvest Sciences says it has produced cannabis biomass in large-scale industrial bioreactors
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) said it has produced cannabis biomass in large-scale industrial bioreactors, representing the completion of the company's cannabis R&D program. On December 8, 2021, BHSC became the first-ever company to announce that it could produce cannabis biomass...
BioHarvest Sciences trademarks its breakthrough non-GMO proven platform technology 'Bio-Plant CELLicitation'
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) revealed that it has trademarked its proprietary non-GMO (genetically modified organisms) biotech platform technology as "Bio-Plant CELLicitation." BioHarvest, which is listed on the Canadian Securities Exchange and has offices in Rehovot, Israel, said the new trademark "Bio-Plant...
Source: https://incomestatements.info
Category: Stock Reports